Benralizumab

證據等級: L5

預測適應症: 5 個

Benralizumab: From Severe Eosinophilic Asthma to Dermatitis

One-Sentence Summary

Benralizumab (Fasenra) is an anti-IL-5 receptor alpha (IL-5Rα) monoclonal antibody approved internationally as add-on maintenance treatment for severe eosinophilic asthma. The TxGNN model predicts it may be effective for Dermatitis, with 6 clinical trials and 20 publications currently supporting this direction. Critically, the pivotal Phase 2 HILLIER trial reported no clinical benefit for general atopic dermatitis; the eosinophil-predominant DRESS subtype (Drug Reaction with Eosinophilia and Systemic Symptoms) remains a mechanistically plausible and actively investigated niche.

Quick Overview

Item	Content
Original Indication	Severe eosinophilic asthma — add-on maintenance treatment (approved internationally; not registered in New Zealand)
Predicted New Indication	Dermatitis
TxGNN Prediction Score	99.16%
Evidence Level	L2 (1 Phase 2 RCT — terminated early, negative primary endpoint for general AD)
New Zealand Market Status	Not Marketed
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails (DRESS subtype only)

Why is This Prediction Reasonable?

Benralizumab is an afucosylated monoclonal antibody that targets the alpha subunit of the IL-5 receptor (IL-5Rα), expressed on eosinophils and basophils. Upon binding, it recruits NK cells via its Fc region to trigger antibody-dependent cell-mediated cytotoxicity (ADCC), achieving near-complete depletion of circulating and tissue eosinophils within days. This rapid and profound eosinophil-depleting mechanism is the basis of its proven efficacy in severe eosinophilic asthma — and provides the theoretical rationale for exploring eosinophil-driven skin conditions.

Atopic dermatitis (AD) is a Th2-predominant inflammatory skin disease characterized by tissue eosinophilia, mast cell activation, and IgE-mediated immune dysregulation. Eosinophils infiltrate AD skin lesions and release toxic granule proteins (MBP, ECP) that contribute to barrier damage and itch. Basophils participate in IgE-mediated acute-phase reactions. IL-5Rα depletion theoretically could attenuate local Th2 inflammation in skin — and a 2025 translational study (PMID 40781582) confirmed that benralizumab does deplete IL-5Rα-bearing cells in AD skin lesions, establishing proof of cellular mechanism.

Despite this biological plausibility, clinical reality has diverged from the mechanistic rationale. The multinational, double-blind, placebo-controlled HILLIER Phase 2 RCT (NCT04605094, n=194) was terminated early and reported no significant improvement in AD signs or symptoms (PMID 37178404, 2023). This indicates that eosinophil depletion alone is insufficient to achieve clinical benefit in most AD patients — likely because dupilumab-targetable IL-4/IL-13 pathways are the dominant drivers. The more mechanistically justified niche is DRESS, a severe eosinophil-predominant drug hypersensitivity reaction where eosinophils play a central, not supporting, pathogenic role. An ongoing Phase 2 study (NCT06734884, n=96) is testing this hypothesis directly.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT04605094	Phase 2	Terminated	194	HILLIER study — multinational double-blind RCT vs placebo in moderate-to-severe AD. Terminated early; primary endpoint not met. Benralizumab showed no significant clinical benefit over placebo in general atopic dermatitis
NCT06734884	Phase 2	Not Yet Recruiting	96	Anti-IL-5Rα (benralizumab) vs standard care in DRESS — a severe eosinophil-driven drug hypersensitivity reaction. High mechanistic alignment; results expected 2029
NCT03563066	Phase 2	Completed	20	Mechanistic study in AD: confirmed benralizumab depletes eosinophils, basophils, and ILC2s in skin lesions. Small sample (n=20) limits clinical efficacy conclusions; primarily provides biomarker data
NCT06477653	Phase 2	Recruiting	30	Dupilumab add-on therapy for hypereosinophilic syndrome (HES) in patients with partial response to eosinophil-depleting biologics (including benralizumab); indirect relevance to eosinophilic skin disease management
NCT04126499	N/A	Completed	28	Retrospective observational study of benralizumab in severe eosinophilic asthma patients (Spain individualized access programme); skin findings incidental, evidence grade low
NCT04763447	Phase 4	Recruiting	234	Omalizumab withdrawal in well-controlled severe allergic asthma; benralizumab is not the primary agent — indirect relevance to atopic comorbidity phenotyping only

Literature Evidence

PMID	Year	Type	Journal	Key Findings
37178404	2023	Phase 2 RCT	JEADV	HILLIER trial primary result: benralizumab shows no significant effect on signs and symptoms of moderate-to-severe atopic dermatitis — the pivotal negative finding for general AD
38695680	2024	Phase 2 RCT	Immunotherapy	HILLIER plain-language summary confirming negative primary endpoints; provides accessible interpretation of the trial's null result
40781582	2025	Translational	Clin Transl Allergy	Benralizumab confirmed to deplete IL-5Rα-bearing cells in AD skin lesions — proof of cellular mechanism, but depletion alone did not translate to clinical improvement
39600395	2024	Review	Allergologie select	Comprehensive update on biologics for atopic diseases; benralizumab reviewed alongside dupilumab and IL-13 inhibitors — current evidence does not support an AD indication
36355314	2023	Review	Dermatol Ther	Combination of dupilumab with other monoclonal antibodies for AD comorbidities; discusses safety considerations for benralizumab co-administration
36411004	2023	Review	Immunol Allergy Clin North Am	Biologics for atopic diseases (including AD) during pregnancy and lactation; safety data for benralizumab in pregnancy remains limited
35987486	2022	Review	J Allergy Clin Immunol Pract	Safety review of 7 FDA-approved biologics including benralizumab during pregnancy; maternal and fetal outcome data summarized for 7 agents
38074921	2024	Case Report	Respirology Case Rep	Dual biologic therapy (benralizumab + dupilumab) in two patients with severe asthma and AD comorbidity; combined phenotype showed improvement suggesting complementary pathways
33236428	2020	Review	Pediatr Allergy Immunol	Anti-IL-5 biologics in pediatric allergic diseases including AD; IL-5 pathway reviewed as candidate target, but clinical evidence for paediatric AD remains absent
31690400	2019	Review	Allergy Asthma Proc	Overview of immunobiologics for severe asthma, AD, and urticaria; benralizumab positioned for asthma, not AD — reflects pre-HILLIER landscape

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: The pivotal HILLIER Phase 2 RCT clearly demonstrates that benralizumab is ineffective for general moderate-to-severe atopic dermatitis, ruling out broad AD as a repurposing target. However, the eosinophil-predominant DRESS subtype represents a mechanistically distinct and justified niche — NCT06734884 (Phase 2, n=96) is currently testing this hypothesis directly, and benralizumab's proven ability to deplete IL-5Rα-bearing cells in skin tissue provides biological support for monitoring this trial's outcome.

To proceed, the following is needed:

Await results of NCT06734884 (DRESS Phase 2; estimated completion September 2029)
Obtain benralizumab package insert to complete contraindications and key warning data (currently unavailable in this dataset)
Query DrugBank API to retrieve formal MOA documentation for mechanistic-link analysis
Define eosinophil-threshold criteria for patient subgroup selection (DRESS vs general AD vs HES-associated skin disease) before any clinical protocol development
Reassess New Zealand market entry pathway if NCT06734884 reports positive efficacy in DRESS
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.